ADMA Biologics, Inc.

NasdaqGM:ADMA Stock Report

Market Cap: US$1.5b

ADMA Biologics Management

Management criteria checks 3/4

ADMA Biologics' CEO is Adam Grossman, appointed in Jan 2007, has a tenure of 17.25 years. total yearly compensation is $6.04M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 1.3% of the company’s shares, worth $19.46M. The average tenure of the management team and the board of directors is 2.3 years and 11.8 years respectively.

Key information

Adam Grossman

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage12.4%
CEO tenure17.3yrs
CEO ownership1.3%
Management average tenure2.3yrs
Board average tenure11.8yrs

Recent management updates

Recent updates

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

ADMA Biologics: 2021 Was Tough

Jan 18

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Dec 02
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: Turning A Corner

Nov 20

ADMA: Insiders Showing Their Cards

Nov 02

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock

Aug 22

ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report

Aug 14

CEO Compensation Analysis

How has Adam Grossman's remuneration changed compared to ADMA Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$6mUS$750k

-US$28m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$3mUS$637k

-US$66m

Sep 30 2022n/an/a

-US$70m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$618k

-US$72m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$74m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$600k

-US$76m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$536k

-US$48m

Sep 30 2019n/an/a

-US$56m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$2mUS$536k

-US$66m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$61m

Mar 31 2018n/an/a

-US$55m

Dec 31 2017US$3mUS$494k

-US$44m

Compensation vs Market: Adam's total compensation ($USD6.04M) is about average for companies of similar size in the US market ($USD5.61M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.


CEO

Adam Grossman (46 yo)

17.3yrs

Tenure

US$6,039,649

Compensation

Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...


Leadership Team

NamePositionTenureCompensationOwnership
Adam Grossman
Co-Founder17.3yrsUS$6.04m1.3%
$ 19.5m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board17.3yrsUS$284.72k0.21%
$ 3.2m
Kaitlin Kestenberg
COO & Senior VP of Complianceno datano data0.048%
$ 722.6k
Drew Pantello
Vice President of Marketing & Corporate Developmentno datano datano data
Cindy Petersen
Executive Director of Human Resources2.3yrsno datano data
Skyler Bloom
Senior Director of Business Development & Corporate Strategyno datano datano data

2.3yrs

Average Tenure

46yo

Average Age

Experienced Management: ADMA's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adam Grossman
Co-Founder17.3yrsUS$6.04m1.3%
$ 19.5m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board17.3yrsUS$284.72k0.21%
$ 3.2m
Bryant Fong
Independent Director11.9yrsUS$280.72k0.026%
$ 385.7k
Steven Elms
Independent Chairman17.3yrsUS$290.22k0.023%
$ 337.5k
Young Kwon
Independent Director2.5yrsUS$272.34k0.12%
$ 1.8m
Michael Green
Member of Scientific Advisory Boardno datano datano data
Lawrence Guiheen
Independent Director11.8yrsUS$275.09k0.056%
$ 843.0k
Roy Chemaly
Member of Scientific Advisory Board9.8yrsno datano data
Jordan Orange
Member of Scientific Advisory Board9.8yrsno datano data
Alison Finger
Independent Directorless than a yearUS$231.12kno data
Jean-Laurent Casanova
Member of Scientific Advisory Boardno datano datano data
Ann Falsey
Member of Scientific Advisory Boardno datano datano data

11.8yrs

Average Tenure

58yo

Average Age

Experienced Board: ADMA's board of directors are seasoned and experienced ( 11.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.